Leidner, R. S., Ambady, P., Lin, E., Jooya, N., Ruiz, A., Darus, C. J., Niemi, C., Zheng-Lin, B., Foote, T., Drokin, A., Tran, A., DuRaine, G., Hanes, D. A., Redmond, W. L., Fox, B. A., Korman, A., Taylor, M. H. (2026). A first-in-human phase I clinical trial evaluating the safety, tolerability, and preliminary efficacy of the novel fas ligand (FasL) inhibitor M3T01 in adults with advanced solid tumors.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.tps2670